Roche Holding AG (RHHBY)
- Previous Close
30.02 - Open
30.10 - Bid --
- Ask --
- Day's Range
30.07 - 30.28 - 52 Week Range
29.80 - 40.48 - Volume
2,819,799 - Avg. Volume
2,687,666 - Market Cap (intraday)
195.277B - Beta (5Y Monthly) 0.15
- PE Ratio (TTM)
15.43 - EPS (TTM)
1.96 - Earnings Date --
- Forward Dividend & Yield 1.39 (4.60%)
- Ex-Dividend Date Mar 14, 2024
- 1y Target Est
37.86
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.
www.roche.com103,605
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: RHHBY
![[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 2% (CER) in first quarter with both divisions growing in high single digit ex COVID-19](https://s.yimg.com/uu/api/res/1.2/3tujng84jArYxPYsssA04w--~B/Zmk9ZmlsbDtoPTYzO3B5b2ZmPTA7dz04NDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/84b0110bbf60eb8397db0461bc3549c4.cf.webp)
Performance Overview: RHHBY
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RHHBY
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RHHBY
Valuation Measures
Market Cap
195.28B
Enterprise Value
217.49B
Trailing P/E
15.47
Forward P/E
12.50
PEG Ratio (5yr expected)
1.24
Price/Sales (ttm)
2.94
Price/Book (mrq)
6.02
Enterprise Value/Revenue
3.60
Enterprise Value/EBITDA
11.73
Financial Highlights
Profitability and Income Statement
Profit Margin
19.02%
Return on Assets (ttm)
12.44%
Return on Equity (ttm)
37.86%
Revenue (ttm)
60.44B
Net Income Avi to Common (ttm)
11.5B
Diluted EPS (ttm)
1.96
Balance Sheet and Cash Flow
Total Cash (mrq)
10.51B
Total Debt/Equity (mrq)
92.75%
Levered Free Cash Flow (ttm)
8.6B
Research Analysis: RHHBY
Company Insights: RHHBY
RHHBY does not have Company Insights
Research Reports: RHHBY
Analyst Report: Roche Holding AG
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
RatingPrice TargetAnalyst Report: Roche Holding AG
Roche Holding AG operates through two segments: Diagnostics and Pharmaceuticals. The Pharmaceutical segment focuses on oncology, immunology, ophthalmology, infectious diseases and neuroscience, and the Diagnostics segment specializes in in vitro diagnostics. Headquartered in Basel, Switzerland, the company was founded by Fritz Hoffmann-La Roche in 1896. The company has approximately 103,605 employees. Roche has substantial market shares in oncology treatments and in vitro diagnostics, and is working to combine its expertise in these areas to develop personalized medicines based on the genetic characteristics of patients. In addition to organic growth, the company has a growth-by-acquisition strategy.
RatingPrice TargetMarket Digest: M, NTAP, NYT, BCE, RHHBY, BHF, UBER, ALC, VTRS
March 4, 2024 Monday Tee Up: Jobs, Powell, COST
Analyst Report: Roche Holding AG
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
RatingPrice Target